<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - GLYCOPYRRONIUM BROMIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>GLYCOPYRRONIUM BROMIDE</h1>

        <p><a href="../drugClass/PHP34659.html">ANTIMUSCARINICS (SYSTEMIC)</a><a href="../drugClass/PHP34556.html">ANTIMUSCARINICS (INHALED)</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Iontophoretic treatment of hyperhidrosis</span>,
            </h4>
            <p class="specificity"><span class="route">To the skin</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Only 1 site to be treated at a time, mximum 2 sites treated in any 24 hours, treatment not to be repeated within 7 days (consult product literature).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Premedication at induction</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection or by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                200&#8211;400 micrograms, alternatively 4&#8211;5 micrograms/kg (max. per dose 400 micrograms).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Intra-operative bradycardia</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                200&#8211;400 micrograms, alternatively 4&#8211;5 micrograms/kg (max. per dose 400 micrograms), repeated if necessary.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Control of muscarinic side-effects of neostigmine in reversal of non-depolarising neuromuscular block</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10&#8211;15 micrograms/kg, alternatively, 200 micrograms per 1 mg of neostigmine to be administered.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Bowel colic in palliative care</span>,
                <span class="indication">Excessive respiratory secretions in palliative care</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                200 micrograms every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                0.6&#8211;1.2 mg/24 hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Maintenance treatment of chronic obstructive pulmonary disease</span>,
            </h4>
            <p class="specificity"><span class="route">By inhalation of powder</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                50 micrograms once daily.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>For inhalation of powder, each 50&#8239;microgram capsule of glycopyrronium delivers 44&#8239;micrograms of glycopyrronium.</p>
            </section>
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>Manufacturer advises use only if potential benefit outweighs risk.</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>Use with caution if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> insomnia,
              </p>
              <p>
                <strong>uncommon:</strong> epistaxis, hyperglycaemia, hypoaesthesia, malaise, rhinitis,
              </p>
              <p>
                <strong>notKnown:</strong> tingling at administration site,
              </p>
        
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use</h3>
                <p class="title">Topical use</p>
              <p>The possibility of systemic side-effects should be considered; however; glycopyrrhonium is poorly absorbed and systemic effects unlikely with topical use.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>Patients or carers should be given advice on how to administer glycopyrronium for inhalation.</p>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
              <p>Antimuscarininc drugs used for premedication to general anaesthesia should only be administered by, or under the direct supervision of, personnel experienced in their use.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>When used by inhalation:</strong>
            arrhythmia (excluding chronic stable atrial fibrillation)
          </li>
          <li>
              <strong>When used by inhalation:</strong>
            history of myocardial infarction
          </li>
          <li>
              <strong>When used by inhalation:</strong>
            history of QT-interval prolongation
          </li>
          <li>
              <strong>When used by inhalation:</strong>
            left ventricular failure
          </li>
          <li>
              <strong>When used by inhalation:</strong>
            unstable ischaemic heart disease
          </li>
        </ul>
        <ul>
          <li>
              <strong>With <ph outputclass="route">topical</ph> use:</strong>
            <p>Cautions applicable to systemic use should be considered; however, glycopyrronium is poorly absorbed and systemic effects unlikely with topical use.</p>
          </li>
        </ul>
      </section>













      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of GLYCOPYRRONIUM BROMIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,
            cream,
            capsule,
            ointment,
            liquid,

            <div id="PHP75142"><a href="../medicinalForm/PHP75142.html" data-target="#PHP75142" data-action="load">Tablet</a></div>
            <div id="PHP75128"><a href="../medicinalForm/PHP75128.html" data-target="#PHP75128" data-action="load">Solution for injection</a></div>
            <div id="PHP75156"><a href="../medicinalForm/PHP75156.html" data-target="#PHP75156" data-action="load">Inhalation powder</a></div>
            <div id="PHP75135"><a href="../medicinalForm/PHP75135.html" data-target="#PHP75135" data-action="load">Powder for solution for iontophoresis</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
